Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dr. Reddy’s Labs Vice Chairman G. V. Prasad On Challenges And Opportunities In The Global Generic Drugs Industry: An Interview With PharmAsia News

This article was originally published in PharmAsia News

Executive Summary

In the ever-evolving pharmaceutical world, where Big Pharma is increasingly seeing common goals in aligning with generic drug companies, GlaxoSmithKline and Dr. Reddy's Labs recently entered into a strategic alliance to reach out to untapped emerging markets for generic drugs. While it is apparent that large pharmaceutical companies see emerging markets as their next big bet, how are generic drug makers responding? To find out, PharmAsia News India bureau caught up with G.V. Prasad, vice chairman of Dr. Reddy's Labs, who shaped the future for his company, from generic drugs to researching new compounds.

You may also be interested in...



Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.

Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

The Indian company has captured over half of the rituximab segment in the local market, earning close to $6 million in just over a year's time after launch of Rituxan generic Reditux.

India's Dr. Reddy's Has All Guns Blazing On Biosimilars; Plans To Go After Top 10

HYDERABAD, India - Enthused by the success of its first monoclonal antibody Reditux - a copy of Genentech's Rituxan (rituximab) - India's Dr. Reddy's Labs is making a full throttle attempt to develop and launch copies of most blockbuster biotech drugs available in the international markets

Related Content

Latest News
UsernamePublicRestriction

Register

SC071971

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel